Advocacy intelligence hub — real-time data for patient organizations
National Cancer Institute (NCI) — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Enhertu
(fam-trastuzumab deruxtecan-nxki)Orphan drugacceleratedDaiichi Sankyo, Inc.
12.1 Mechanism of Action Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The s...
Browse all Peripheral primitive neuroectodermal tumor news →
Helen E Heslop, MD, MD
Baylor College of Medicine
📍 HOUSTON, TX
Sarah E Leary, M.D
Children's Oncology Group
📍 SEATTLE, WA
Brian Kushner, MD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Mark A Ranalli, MD, MS
Nationwide Children's Hospital
📍 WEXFORD, PA
Meredith S Irwin
Children's Oncology Group
📍 CINCINNATI, OH
Susan K. Parsons, MD, MRP
Tufts Medical Center Cancer Center
View all Peripheral primitive neuroectodermal tumor specialists →